tbuckley/cabot-search huggingface dataset:
Relationship Between the Lethal Yellow (&lt;italic&gt;A&lt;/italic&gt;&lt;sup&gt;&lt;italic&gt;y&lt;/italic&gt;&lt;/sup&gt;) Gene of the Mouse and Susceptibility to Induced Pulmonary Tumors
Authors: W. E. Heston
Journal: JNCI Journal of the National Cancer Institute (1942)

Relationship Between the Lethal Yellow (A y ) Gene of the Mouse and Susceptibility to Induced Pulmonary Tumors Get access W. E. Heston W. E. Heston geneticist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 3, December 1942, Pages 303–308, https://doi.org/10.1093/jnci/3.3.303 Published: 01 December 1942
Performance of<sup>18</sup>F-FET-PET versus<sup>18</sup>F-FDG-PET for the diagnosis and grading of brain tumors: inherent bias in meta-analysis not revealed by quality metrics: Table 1.
Authors: Xiangyan Huang, Harrison Bai, Hao Zhou, Haiyun Tang, Li Yang
Journal: Neuro-Oncology (2016)
AB0390 Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics: Baseline Data of the Carma Project
Authors: S. Castañeda, M.A. Martin Martinez, C. Gonzalez Juanatey, J. Llorca, M.J. Garcia Yebenes, S. Perez Vicente, J.T. Sanchez Costa, F. Diaz Gonzalez, M.A. Gonzalez Gay
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To establish the cardiovascular (CV) morbidity and associated risk factors for CV disease (CVD) in Spanish patients with chronic inflammatory rheumatic diseases (CIRD) and unexposed individuals attending rheumatology clinics <h3>Methods</h3> Analysis of data from the baseline visit of a 10-year prospective study (CARdiovascular in rheuMAtology-CARMA-project) that includes a cohort of patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)] and another cohort of matched individuals without CIRD attending outpatient rheumatology clinics from sixty-seven hospitals in Spain. Prevalence of CV morbidity, CV risk factors and systematic coronary risk evaluation (SCORE) assessment were analyzed <h3>Results</h3> 2,234 patients (775 RA, 738 AS and 721 PsA) and 677 unexposed subjects were included. A high percentage of patients had low disease activity at the time of recruitment. PsA patients had more commonly classic CV risk factors and metabolic syndrome features than did the remaining individuals. Prevalence of CVD was higher in RA (10.5%) than in AS (7.6%), PsA (7.2%) and unexposed individuals (6.4%). A multivariate analysis adjusted for the presence of classic CV risk factors and disease duration revealed a positive trend for CVD in RA (OR=1.58; 95%CI=0.90-2.76; p=0.10) and AS (OR=1.77; 95%CI=0.96-3.27; p=0.07). Disease duration in all CIRD groups (RA: OR=1.06; 95%CI=1.01-1.11; AS: OR=1.06; 95%CI=1.01-1.06; PsA: OR=1.15; 95%CI=1.07-1.23) and functional capacity (HAQ) in RA (OR=2.15; 95%CI=1.29-3.56; p=0.003) were associated with an increased risk of CVD. Most patients had a moderate CV risk according to the SCORE charts. <h3>Conclusions</h3> Despite recent advances in the management of CIRD, prevalence of CVD remains increased in Spanish subjects with CIRD attending outpatient rheumatology clinics. <h3>Disclosure of Interest</h3> S. Castañeda: None declared, M. A. Martin Martinez: None declared, C. Gonzalez Juanatey: None declared, J. Llorca: None declared, M. J. Garcia Yebenes: None declared, S. Perez Vicente: None declared, J. T. Sanchez Costa: None declared, F. Diaz Gonzalez: None declared, M. A. Gonzalez Gay Grant/research support from: This project has been supported by an unrestricted grant from Abbvie, Spain. The design, analysis, interpretation of results and preparation of the manuscript has been done independently of Abbvie. Dr. González-Gay9s studies have been supported by grants from "Fondo de Investigaciones Sanitarias" PI06/0024, PS09/00748 and PI12/00060, and RD12/0009/0013 (RIER) from "Instituto de Salud Carlos III" (ISCIII) (Spain).
Endoscopic Mechanical Lithotripsy for the Treatment of Common Bile Duct Stone
Authors: T Higuchi, Y Kon
Journal: Endoscopy (1987)

Using a newly designed basket catheter, endoscopic mechanical lithotripsy was attempted in 14 patients with common bile duct stones following endoscopic sphincterotomy, and was successful in all cases. Endoscopic mechanical lithotripsy is a supplementary means of removing common bile duct stones after endoscopic sphincterotomy, and its usefulness is highly rated. In some cases, however, there is difficulty in inserting the basket catheter into the common bile duct and grasping the gallstone. The newly designed forceps was accordingly developed, to smash these bile duct stone more reliably and effectively.
Lung Organ-Specific Antigens on Cells With HeLa Marker Chromosomes
Authors: Walter A. Nelson-Rees
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Lung Organ-Specific Antigens on Cells With HeLa Marker Chromosomes Get access Walter A. Nelson-Rees Walter A. Nelson-Rees Naval Biosciences Laboratory School of Public Health University of California, Oakland, California 94625 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 6, June 1978, Pages 1205–1206, https://doi.org/10.1093/jnci/60.6.1205 Published: 01 June 1978
Epiglottic Squamous Cell Carcinoma Showing Unexpected 18F-FDOPA Uptake on PET/CT Investigation
Authors: Sebastien Dietemann, Christian Debry, Aline Onea, Izzie Jacques Namer, Alessio Imperiale
Journal: Clinical Nuclear Medicine (2015)

We report the unexpected findings of ¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-FDOPA) PET/CT performed in a patient with a history of ileal carcinoid. A focally increased ¹⁸F-FDOPA uptake was detected in the left side of the epiglottis corresponding to a laryngeal squamous cell carcinoma. Interestingly, uptake of 3-O-methyl-6-¹⁸F-fluoro-L-dihydroxyphenylalanine, a metabolite of ¹⁸F-FDOPA, has been previously reported in both squamous cell carcinoma cell lines and the corresponding mouse tumor xenograft models. Although ¹⁸F-FDOPA is mainly used in patients with neuroendocrine tumors, ¹⁸F-FDOPA is not a neuroendocrine tumor-specific radiotracer.
Brief Report: Anti–Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis
Authors: Zoe E. Betteridge, Felix Woodhead, Hui Lu, Gavin Shaddick, Christopher C. Bunn, Christopher P. Denton, David J. Abraham, Roland M. du Bois, Mervyn Lewis, Athol U. Wells, Neil J. McHugh
Journal: Arthritis & Rheumatology (2016)

To investigate novel systemic sclerosis (SSc) autoantibodies in autoantibody-negative patients and establish clinical associations.Serum samples and clinical data for 548 patients with SSc were collected. Routine serologic techniques were used to test the serum samples for known SSc autoantibodies, and samples with negative results were further investigated by radiolabeled-protein immunoprecipitation assay. Sera that immunoprecipitated a novel 30-kd band were analyzed by indirect immunofluorescence and immunoprecipitation, using depleted cell extracts to establish a common reactivity. Mass spectrometry was performed to identify the novel autoantigen, and the results were confirmed using commercial antibodies. Sera from 426 patients with other forms of connective tissue disease, 103 with rheumatoid arthritis, 114 with idiopathic interstitial lung disease (ILD), and 150 healthy subjects were serotyped as controls.A novel autoantigen with a molecular weight of ∼30 kd was recognized by 7 sera from patients with SSc, 6 of whom had ILD, and by no controls. Six of the patients had diffuse cutaneous involvement, and 4 had overlap features with other autoimmune diseases. Immunodepletion experiments indicated that all samples targeted the same autoantigen, and mass spectrometry identified the novel autoantigen as eukaryotic initiation factor 2B (eIF2B).We report the identification of a novel autoantibody (anti-eIF2B) in a small number of patients with SSc (∼1%); this autoantibody is closely associated with diffuse cutaneous manifestations and the presence of ILD.
Modeling Resistance To Tyrosine Kinase Inhibitors In TEL/ABL-Positive Acute Lymphoblastic Leukemia
Authors: Olga Zimmermannova, Jan Zuna, Katerina Machova Polakova, Libuse Lizcova, Zuzana Zemanova, I-Ming L. Chen, JH Frederik Falkenburg, Richard C. Harvey, Cheryl L. Willman, Jan Trka, Marketa Zaliova
Journal: Blood (2013)
Patient-therapist matching: a research evaluation
Authors: J G Gunderson
Journal: American Journal of Psychiatry (1978)

The author tested the predictive power of 10 hypotheses about the personality qualities of therapists that match with those of schizophrenic inpatients to affect therapeutic course. The personality matching traits predicted with significant accuracy the quality of the therapeutic relationship and even the type of overall clinical outcome. Examination of the data revealed that most of this surprising predictive strength derived from a group of highly intercorrelated personality qualities. Taken together, these qualities reflected a capacity of therapists to be comfortable while being involved with a variety of strong affects in their schizophrenic inpatients. The limitations of this study and its advantages over the A-B typology are discussed.
ELECTROSHOCK THERAPY
Authors: PAUL H. WILCOX
Journal: American Journal of Psychiatry (1947)

1. Forty percent of the most chronic patients showed significant improvement in ward behavior if adequately and repeatedly treated with suitable type of electroshock therapy. Relapses must be treated whenever they occur over months and years. 2. At least 60% of early cases, aged 60 or under, were rehabilitated within 1 year when adequately treated and 65% by the end of the second year after the start of treatment. 3. Adequate treatment means intensive treatment until the expected improvement has occurred and intensive treatment of relapses when they occur. No patient, otherwise suitable who still is not rehabilitated after 1 year, has had an adequate trial of treatment with less than 20 treatments. 4. An ideal therapy is one which achieves beneficial results without causing accumulating brain damage, thus permitting its use repeatedly for years if necessary. 5. This ideal is approached by the relatively low intensity 60-cycle pulsating direct current used in the treatment of the patients reviewed in this paper. This technique also has been accompanied by an exceptionally low percentage of skeletal complications.
Inguinal Hernia Detected During Bone Scintigraphy
Authors: GÜLGÜN BÜYÜKDERELI
Journal: Clinical Nuclear Medicine (2001)

From the Department of Nuclear Medicine, Çukurova University Faculty of Medicine, Adana, Turkey Received for publication May 3, 2000. Revision accepted July 27, 2000. Correspondence: Gülgün Büyükderel˙i, Kurtuluş mah. Ziyapaşa Bulvarı, Büşra apt. Apt No:10 Daire No:15, 01120 Seyhan Adana, Turkey. E-mail: [email protected]
&lt;emph type="ital"&gt;Licking Valley&lt;/emph&gt;
Authors: Jeanette M. Smith
Journal: JAMA (2008)

“We need the tonic of wildness. . . . We can never have enough of Nature” (Walden; or, Life in the Woods, Henry David Thoreau, 1854). These sentiments aptly describe the lifelong muse of kindred spirit Robert H. Whitmore (1890-1979), whose sympathy with nature emanates from his landscape paintings.
Send This Patient's Tumor for Culture and Sensitivity
Authors: Daniel D. Von Hoff
Journal: New England Journal of Medicine (1983)

One of the primary goals in caring for patients with malignant disease is to provide a treatment program that maximizes the chance of survival and minimizes the side effects of therapy. This goal is particularly important in chemotherapy for cancer.In 1978, Salmon and colleagues1 reported a new in vitro test for determining the sensitivity or resistance of an individual patient's tumor to an anticancer drug. To perform the test, now called the human tumor stem-cell assay, tumor is removed from the patient, made into a suspension of single cells, exposed to the anticancer drug in vitro, and then cultured . . .
Day-and-Night Closed-Loop Control Using the Unified Safety System in Adolescents With Type 1 Diabetes at Camp
Authors: Trang T. Ly, Bruce A. Buckingham, Daniel J. DeSalvo, Satya Shanmugham, Marta Satin-Smith, Mark D. DeBoer, Mary C. Oliveri, Elaine Schertz, Marc D. Breton, Daniel R. Cherñavvsky
Journal: Diabetes Care (2016)

Adolescence marks a challenging time in diabetes care (1). Automated insulin delivery has the potential to overcome some of the barriers, such as missed meal boluses and nocturnal hypoglycemia. The University of Virginia Unified Safety System (USS) is one of the most tested control-to-range approaches and operates on an Android-based system that uses a Dexcom G4 PLATINUM Share glucose sensor and Roche Accu-Chek pump (2). The objective of this study was to test the efficacy of USS in day-and-night closed-loop control (CLC) in adolescents with type 1 diabetes at camp, where large meals and physical activity challenge glucose control.

In this study, eligible subjects with type 1 diabetes on pump therapy were randomized to either CLC ( n = 17) or sensor-augmented pump (SAP) ( n = 16) for 5 days. There was no A1C restriction.

Clinical characteristics of the 33 subjects include mean ± SD (min–max) age of 17.9 ± 5.5 years (10.1–35.0), weight 68 ± 17 kg (37.3–104.3), A1C …
Four-year follow-up of the influence of psychological comorbidity on medical rehospitalization
Authors: S M Saravay, S Pollack, M D Steinberg, B Weinschel, M Habert
Journal: American Journal of Psychiatry (1996)

This study tested the hypothesis that psychiatric comorbidity measured in medical and surgical general hospital inpatients predicts increased readmissions and days spent rehospitalized at the same hospital up to 4 years after discharge.A convenience sample of 273 medical/surgical inpatients aged 18 years and older were given psychological tests during their third to fifth hospital days on medical and surgical units from June 1, 1985, through June 30, 1986. The main outcome measure was the number of medical/surgical readmissions and number of days rehospitalized during a 4-year follow-up at the same institution.Compared to the rest of the study group, the cognitively impaired patients (according to the Mini-Mental State examination) averaged twice as many rehospitalizations and three times as many days rehospitalized at 6-month follow-up and twice as many days rehospitalized at 2-year follow-up. Compared to the rest of the group, the patients who were depressed or who had high interpersonal sensitivity scores at the index admission spent twice as many days rehospitalized during the 4-year follow-up, while the patients with high hostility scores had almost twice as many readmissions. These results remained statistically significant after separate partialing out of the effects of severity of functional impairment, age, cognitive impairment, and number of admissions or days spent hospitalized before the index admission.Psychiatric comorbidity, previously well documented as contributing to increased length of stay in the general hospital, is associated with increased hospital utilization for at least 4 years after discharge.
AB0674 The Erasmus Syndrome: Exposure to Silica and Systemic Sclerosis
Authors: A. Abdessemed, S. Slimani, N. Khaldoun, F. Bougrina, N. Ait Belabas, M. Djoudi, S. Lefkir, N. Brahimi, A. Ladjouze
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The etiology of systemic sclerosis (SSc) is unknown, but there is evidence of environmental factors playing a part in disease development in a number of cases. Silica is a common mineral that is part of sand, rock and mineral ores like quartz. Research evidence has shown that exposure to silica dust might contribute to SSc causation. Erasmus syndrome consists of the association of systemic sclerosis following exposure to silica with or without silicosis <h3>Objectives</h3> To study features of systemic sclerosis in patients exposed to silica <h3>Methods</h3> Clinical records of 200 systemic sclerosis patients fulfilled the American college of rheumatology classification criteria and/or Leroy and Medsger classification criteria, and admitted to rheumatology department between 1986 and 2014, were reviewed. Nine patients had a history of occupational exposure to silica. <h3>Results</h3> All patients were male, with a median age of 30 years and a disease duration (first non-Raynaud symptom) of 2 years. 6 patients had a diffuse scleroderma, 3 patients had a limited scleroderma. The mean exposure time to silica was 5.5 years. All patients had Raynaud9s phenomenon, 7 had digital ulcers. Thoracic high-resolution computed tomography detected a silicotic pattern in nine patients. Seven had restrictive spirographic patterns. 3 patients had pulmonary hypertension. Antitopoisomerase I antibodies was positive in 6 patients. All patients are stone masons in sandstone careers in the region of Tkout (eastern Algeria). They Work unprotected in confined structures, and use chain saw to cut stones. Mineralogical stone study showed significant presence of quartz (more than 95%). <h3>Conclusions</h3> Our patients have severe systemic sclerosis and accelerated silicosis, wich occurs after exposure to large amounts of silica over a shorter period of time. Employers must give their workers, equipment and clothing to protect themselves. <h3>Disclosure of Interest</h3> None declared
Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.
Authors: R. J. Maggiore, C. P. Gross, M. Hardt, W. P. Tew, S. G. Mohile, H. D. Klepin, S. M. Lichtman, C. Owusu, A. Gajra, R. Ramani, V. Katheria, J. Brown, R. Jayani, A. Hurria
Journal: Journal of Clinical Oncology (2011)

e19501 Background: Polypharmacy and potentially inappropriate medication (PIM) use are common among older adults. The goals of this study were: 1) to evaluate the prevalence of polypharmacy and PIM use and 2) to determine the relationship between polypharmacy and PIM use with chemotherapy-related toxicity (tox) in an outpatient population of older adults with cancer (CA). Methods: We evaluated polypharmacy in 500 patients age ≥65 years with CA who were starting a new chemotherapy (chemo) regimen. Polypharmacy was defined by an increased number of medications (meds) taken daily (≥5 meds) based on a prior consensus study (Hajjar et al. 2003). PIM use was defined by 3 indices: the Beers criteria, the Zhan criteria, and the HEDIS Drugs to Avoid in the Elderly (DAE) list. We assessed the baseline frequency of polypharmacy and PIM use, and analyzed their association with the following outcomes utilizing bivariate analyses: grade 3-5 chemo-related tox [NCI Common Toxicity Criteria (v3.0)], hospitalizations during chemo, and chemo modifications (delays, dose reductions, early discontinuation). Results: 500 patients were evaluable [mean age, 73 years (range 65-91); 57% female; 61% stage IV]. The mean number of daily meds per patient was 5 (SD 3.5; range 0-23), with 239 (48%) taking ≥5 meds. Patients taking >5 meds (vs. <5 meds) were more likely to be older (mean, 74 vs. 72 years; P=0.01), male (48% vs. 38%; P=0.04), and married (67% vs. 54%; P<0.01). We identified PIM use in 89 (18%), 53 (11%), and 68 (14%) patients utilizing the Beers criteria, the Zhan criteria, and the HEDIS DAE list, respectively. We did not find an association between the presence of polypharmacy (P=0.353) or PIM use (P=0.350) and any grade 3-5 tox. However, there was an association between presence of polypharmacy and increased incidence of: 1) hospitalization while undergoing chemo (P<0.01); and 2) early discontinuation of chemo (P=0.02). Conclusions: Polypharmacy and PIM use are common in the geriatric oncology population. While polypharmacy did not increase the risk of chemo tox in this cohort, it was associated with a higher frequency of other clinically important adverse events such as hospitalization and early chemo discontinuation.
THU0217 Paradoxical Psoriatic Effects of Anti-TNF Therapy in Patients with Ankylosing Spondylitis
Authors: M. Zlnay, M. Salkova, M. Oetterova, J. Rovensky, I. Rybar
Journal: Annals of the Rheumatic Diseases (2015)

Background  Psoriasis is one of the most common extra-articular manifestations in patients with ankylosing spondylitis (AS). TNF inhibitors (TNFi) are highly effective for signs and symptoms of AS and psoriasis. However, there is some evidence about exacerbation or new onset of cutaneous psoriasis during anti TNF therapy.  Objectives  To examine the incidence rate of worsening or new onset of psoriasis in AS patients during anti-TNF therapy  Methods  AS patients with TNFi were retrospectively analysed in database of patients with biological therapy in Slovakia. This analysis covered AS patients with infliximab, etanercept, adalimumab and golimumab since March 3rd 2003, when the first patient initiated TNFi until December 31st 2013. Duration of anti-TNF treatment was calculated on patient-years (PYs). Disease activity was evaluated by BASDAI, ESR, CRP and global patient assessment of disease activity. History of psoriasis in each patient was explored and worsening of psoriasis or the first episode cases during anti-TNF therapy were analysed. Incidence rate was calculated on 100 PYs, and differences among TNFi were assessed.  Results  385 patients with AS on TNFi were analyzed, of them 327 men (85%) and 58 women (15%). Mean age of patients at the time of initiation of TNF blockers was 39.0 (±10.7) years, median was 37 years (IQR 31-47). Total time on anti-TNF therapy was calculated on 1129 patient-years. 81 patients were exposed to infliximab for a total of 274 PYs, 102 patients were exposed to etanercept for 394 PYs, 155 patients were treated with adalimumab 390 PYs, and 47 patients were under the treatment with golimumab 72 PYs. Cutaneous psoriasis was present in 20 patients (5.2%) in history before starting TNFi – 8 patients on infliximab (9.9%), 8 patients on adalimumab (5.2%), 2 patients on etanercept (2.0%) and 2 patients on golimumab (2.0%). During anti-TNF therapy, exacerbation of cutaneous psoriasis was found only in 2 patients, but first episode cases were described in 6 ones. In every case, dermatologist verified the diagnosis of cutaneous psoriasis, and 50% of all cases had palmo-plantar pustular form of psoriasis, reflecting possible paradoxical reaction of the TNFi. Incidence of paradoxical psoriatic reaction was calculated on 0.71/100 PYs. Relatively more paradoxical psoriatic reactions during anti-TNF therapy were observed in patients with infliximab (1.09/100 PYs) and golimumab (1.41/100 PYs) than in patients with adalimumab and etanercept (both 0.51/100 PYs).  Conclusions  Incidence of paradoxical psoriatic effects of anti-TNF therapy in AS patients is very low. Our findings demonstrate that palmo-plantar pustular psoriasis is the most common form of paradoxical skin lesions. They were less frequent in patients treated with etanercept than in patients treated with monoclonal antibodies infliximab and golimumab.  Disclosure of Interest  None declared